KEI Oral Statement for US ITC Investigation on COVID-19 and TRIPS Agreement Flexibilities

NOTE: KEI also submitted a 16-page in depth written submission to this investigation on March 20, 2023. The US International Trade Commission (ITC) will hold a hearing on March 29-30, 2023 on COVID–19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS… Continue Reading

Cancer patients file administrative appeal on NIH rejection of Xtandi march-in petition with Secretary of HHS Becerra

On March 23, 2023, three prostate cancer patients, Robert Sachs, Clare Love and Eric Sawyer, filed an administrative appeal of the NIH decision to reject petition that HHS use Federal rights in patents on Xtandi to address pricing discrimination against… Continue Reading

Response to Questions to KEI from Trade Policy Staff Committee in Docket No. USTR-2022-0016, Special 301

In 2023, the Office of the US Trade Representative (USTR) has elected to continue conducting its Special 301 Review process virtually, with no in-person hearing, as in the years prior to 2020. In this virtual process, after stakeholders have submitted… Continue Reading